BioMarin is committed to maintaining the highest standards of ethics and transparency in conducting clinical trials. We recognize the importance of diverse participation in clinical trials and strive to include participants of different backgrounds to ensure comprehensive and inclusive research.
We believe that transparency is essential for advancing science and medicine and establishing trust among patients, healthcare providers and the broader medical community. Our research practices, including our commitment to transparency and data sharing, are designed to be fully compliant with all applicable laws and regulations. This is critically important to help protect the safety, well-being and privacy of participants. Some of our practices include:
Committing to these practices enables us to foster trust and confidence in our research, contribute to the advancement of medical knowledge and improve patient care.
It is critical to ensure that clinical trials are representative of the diverse people will ultimately receive a medicine. We are dedicated to building a blueprint for clinical trial diversity (CTD) that is far-reaching, impactful and measurable.
Designing clinical trials for rare conditions poses unique challenges, such as lower prevalence, disease heterogeneity and limited information on disease pathology that make it especially critical to include people of all backgrounds. For these reasons, we believe it is critically important to take a holistic approach when incorporating CTD elements into clinical trials for people with rare conditions.